SC 13G/A - 4D Pharma PLC (0001830162) (Subject)
SC 13G - 4D Pharma PLC (0001830162) (Subject)
SC 13G - 4D Pharma PLC (0001830162) (Subject)
- Primary Efficacy Endpoint Met Early in Renal Cell Carcinoma Group in Part B of Study - Company to Host Conference Call and Webcast Today March 23, 10:00 am EST (2:00 pm GMT) 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that in Part B of its signal finding study of MRx0518 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with solid tumors that have progressed on a prior immune checkpoint inhibitor (ICI), the renal cell carcinoma (RCC) group has met its primary efficacy endpoint ahead of enrollment complet
- Part A of the trial achieved the primary endpoint of safety and tolerability - Multiple secondary endpoints show positive trends in improving asthma control, supporting progression into Part B of the Phase I/II trial - Company to host conference call and webcast to discuss results today at 08:00 a.m. ET (1:00 p.m. GMT) 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces additional clinical data from Part A of its Phase I/II trial of MRx-4DP0004, an orally-delivered single strain Live Biotherapeutic being developed for the treatment of asthma.
Upgrades According to Vertical Research, the prior rating for PPG Industries Inc (NYSE:PPG) was changed from Hold to Buy. PPG Indus earned $1.37 in the first quarter, compared to $1.88 in the year-ago quarter. The stock has a 52-week-high of $177.32 and a 52-week-low of $107.06. At the end of the last trading period, PPG Indus closed at $121.01. OTR Global upgraded the previous rating for Chipotle Mexican Grill Inc (NYSE:CMG) from Mixed to Positive. In the first quarter, Chipotle Mexican Grill showed an EPS of $5.70, compared to $5.36 from the year-ago quarter. The current stock performance of Chipotle Mexican Grill shows a 52-week-high of $1958.55 and a 52-week-low of $1196.28. Moreover,
Chardan Capital analyst Keay Nakae downgrades 4d pharma (NASDAQ:LBPS) from Buy to Neutral.
Gainers Ocean Bio-Chem, Inc. (NASDAQ:OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. Phoenix Motor Inc. (NASDAQ:PEV) jumped 70.5% to close at $5.83. Visionary Education Technology Holdings Group Inc. (NASDAQ:VEDU) gained 47.9% to close at $1.73. Exela Technologies, Inc. (NASDAQ:XELA) gained 39.2% to close at $0.1897 after the company announced a new customer win of $136 million in total contract value. U.S. Well Services, Inc. (NASDAQ:USWS) climbed 37.3% to close at $0.9872 after ProFrac Holding announced plans to acquire the company for $1.21 per share in an all-stock deal.
6-K - 4D Pharma PLC (0001830162) (Filer)
6-K - 4D Pharma PLC (0001830162) (Filer)
6-K - 4D Pharma PLC (0001830162) (Filer)
4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today reported financial results for the full year ending December 31, 2021 and highlighted its key corporate objectives for 2022. "2021 was a productive year for 4D pharma. We reported promising signals in the clinic from our lead candidates in immuno-oncology and inflammatory disease, and entered into our second clinical collaboration in oncology, further validating the potential for single strain Live Biotherapeutics to treat systemic disease and the MicroRx platform. Additionally, we completed the merger wit
4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that on June 27, 2022, it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that in accordance with Listing Rules 5101, 5110(b), and IM-5101-1, Nasdaq Staff (the "Staff") has determined that 4D pharma's securities will be delisted from The Nasdaq Stock Market. Accordingly, trading of 4D pharma's LBPS will be suspended at the opening of business on July 7, 2022, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove 4D pharma's secur
4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, provides an update to the announcement released earlier today regarding the Company's request for an immediate suspension of trading in the Company's ordinary shares on AIM which took effect from 12.30 p.m. (London). On 29 July 2021, the Company announced that it had agreed a senior secured credit facility (the "Facility") for up to US$30m with Oxford Finance LLC ("Oxford"), with an initial tranche of US$12.5 million drawn at closing and further tranches available dependent on the achievement of certain mileston
- Study to assess safety of MRx0518 with BAVENCIO and effect on progression-free survival at 6 months - Study sites are open for patient enrolment 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced the presentation of a trial in progress poster from the Phase II clinical trial of MRx0518 in combination with BAVENCIO® (avelumab), a PD-L1 blocking antibody, as a first-line maintenance therapy for patients with unresectable locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy, a